Fourth quarter revenue results drive record year
DENVER — July 3, 2012 — Corgenix Medical Corporation (OTC QB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today reported that preliminary revenue results continued strong in the fourth quarter (ended June 30, 2012), coming in at approximately $2,328,000. Given the preliminary fourth quarter revenues noted above, the company’s preliminary revenue results for the fiscal year ended June 30, 2012, will be approximately $9,289,000, a new record, 17% over the prior year, and greater than the $9.1 million guidance announced after the third quarter results in May.
“We are pleased to end the year on a high note with a strong fourth quarter resulting in a record year for revenues,” said Douglass Simpson, Corgenix President and Chief Executive Officer. “The recently announced expansion of our Contract Manufacturing program, along with advancements in our various proprietary initiatives show we are moving into the new fiscal year positioned for continued financial improvement.”
Mr. Simpson stated that Management continues to believe that Corgenix will again achieve record revenues and improved bottom line results for the upcoming fiscal year ending June 30, 2013, and expects to release its complete financial results for the recently ended fiscal year on or about September 27, 2012.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic its for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.
Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, which are inherently uncertain, are based on management’s current expectations and are subject to various factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic eports filed with the Securities and Exchange Commission, and in the Company’s subsequent filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation or intend to publicly update or revise any forward-looking statements.
Corgenix Company Contact:
Corgenix Medical Corp.
William Critchfield, Senior VP Operations and Finance, CFO
Corgenix Media Contact:
Vice President and Public Relations Supervisor
Armada Medical Marketing
Phone: 303-623-1190 x 230